Enlivex Therapeutics ( NASDAQ: ENLV ) has entered into a definitive agreement for the issuance and sale in a registered direct offering of an aggregate of 3.57M ordinary shares and warrants, at a purchase price of $1.40 /ordinary share and associated warrants.
The warrants will have an exercise price of $1.40/share and will be exercisable immediately upon issuance. The gross proceeds are expected to be ~$5M and the potential gross proceeds from the warrants, if fully exercised on a cash basis, will be ~$10M.
The Company intends to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on or about May 29, 2024. More on Envilex Therapeutics Enlivex stock plunges 50% on mixed results from sepsis study Seeking Alpha’s Quant Rating on Envilex Therapeutics Historical earnings data for Envilex Therapeutics Financial information for Envilex Therapeutics.
